Porcupine inhibitors impair trabecular and cortical bone mass and strength in mice.

ABSTRACT: WNT signaling is involved in the tumorigenesis of various cancers and regulates bone homeostasis. Palmitoleoylation of WNTs by Porcupine is required for WNT activity. Porcupine inhibitors are under development for cancer therapy. As the possible side effects of Porcupine inhibitors on bone health are unknown, we determined their effects on bone mass and strength. Twelve-week-old C57BL/6N female mice were treated by the Porcupine inhibitors LGK974 (low dose?=?3?mg/kg/day; high dose?=?6?mg/kg/day) or Wnt-C59 (10?mg/kg/day) or vehicle for 3 weeks. Bone parameters were assessed by serum biomarkers, dual-energy X-ray absorptiometry, µCT and histomorphometry. Bone strength was measured by the 3-point bending test. The Porcupine inhibitors were well tolerated demonstrated by normal body weight. Both doses of LGK974 and Wnt-C59 reduced total body bone mineral density compared with vehicle treatment (P?

SUBMITTER: Funck-Brentano T 

PROVIDER: S-EPMC5987170 | biostudies-literature | 2018 Jul

REPOSITORIES: biostudies-literature